Pregnancy-Associated Plasma Protein A, Pappalysin 1 Proteins (PAPPA)

Mouse (Murine) Pregnancy-Associated Plasma Protein A, Pappalysin 1 (PAPPA) interaction partners

1. Inducible knockdown of PAPP-A gene expression in adult female mice extends life span.

2. Intrinsic mitochondrial oxidative capacity was significantly increased in skeletal muscle of aged PAPP-A KO compared to WT mice. Moreover, 18-month-old PAPP-A KO mice exhibited significantly enhanced endurance running on a treadmill. Thus, PAPP-A deficiency in mice is associated with indices of healthy skeletal muscle function with age.

3. Snell, GHKRO, and PAPPA-KO mice express high levels of two proteins involved in DNA repair, O-6-methylguanine-DNA methyltransferase (MGMT) and N-myc downstream-regulated gene 1 (NDRG1).

4. STC2 is involved in regulating PAPP-A activity during the development of atherosclerosis

5. Study demonstrates proof-of-principle and provides feasibility for a novel therapeutic strategy to inhibit atherosclerotic plaque burden by selective targeting of PAPP-A.

6. stimulation of PAPP-A expression by intermittent PTH treatment contributes to PTH bone anabolism in mice

7. PAPP-A affects fascicle structure, thereby affecting tendon phenotype.

8. tissue-specific expression differentially affected during aging

9. PAPP-A has a role in development of advanced plaque with necrotic cores and buried fibrous caps in the brachiocephalic artery

10. these data indicate preferential impact of PAPP-A deficiency on visceral fat in the mouse that is associated with enhanced insulin receptor signaling

11. Studies show a conditional PAPP-A knockout (KO) model for efficacy of tamoxifen-induced floxed PAPP-A excision in various tissues and indicate a significant reduction of neointimal formation after unilateral carotid artery ligation.

12. absence of PAPP-A is associated with resistance to the development of indicators of diabetic nephropathy in mice

13. Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation.

14. Data conclude that PAPP-A proteolytic activity is required for the lesion-promoting effect of PAPP-A and that its specificity must be directed against IGFBP-4.

15. observations revealed a novel function of prohibitin as a chaperone of p53. Further, they suggest that binding of denatured p53 in intron 1 causes an enhancer effect and increases the transcription of PAPP-A

16. PAPP-A increases bone formation primarily by increasing IGF bioavailability and other alternative pathways may play a negligible role in mediating the anabolic effect of PAPPA in bone.

17. PAPPA modulates ovarian function and female fertility by controlling the bioavailability of ovarian insulin-like growth factors.

18. Renal expression of Irs1 and Mt1 was increased by PappA(-/-) as well as by mutations that reduce IGF-1 in serum.

19. Major contributors to extended life span of PAPP-A knockout mice are delayed occurrence of fatal neoplasias and decreased incidence of age-related degenerative changes.

20. gonadotropin-stimulated PAPP-A gene expression plays a role in the follicle development, ovulation, and luteogenesis in the mammalian ovary

Human Pregnancy-Associated Plasma Protein A, Pappalysin 1 (PAPPA) interaction partners

1. In STEMI patients, Stanniocalcin-2 and IGFBP-4 emerged as independent predictors of all-cause death and readmission due to HF. The Stanniocalcin-2/PAPP-A/IGFBP-4 axis exhibits a significant role in STEMI risk stratification.

2. In summary, this study suggests that PAPPA is essential to maintain a receptive endometrium by up-regulating N-fucosylation, which is a potential useful biomarker to evaluate the receptive functions of the endometrium.

3. Serum PAPP-A at third trimester of pregnancy was not associated with late-onset pre-eclampsia and intrauterine growth retardation after 34weeks of pregnancy.

4. Elevated PROK1 in the first pregnancy trimester is a more effective marker than PAPP-A in the prediction of pre-eclampsia and fetal growth restriction.

5. The findings suggest a possible pathophysiological link between the development of Fetal growth restriction and the expression of PAPPA, PAPPA2 and PLAC-1.

6. Data suggest that PGF and PAPPA serve as serum biomarkers for early diagnosis of gestational hypertension. These studies were conducted at antenatal clinics in Ghana using blood from women between 8 and 13 weeks gestation. (PGF = placental growth factor; PAPPA = pregnancy-associated plasma protein-A)

7. Pregnancy associated plasma protein-A (PAPP-A) appears to be a potentially useful biomarker for short-term risk stratification of patients presenting with chest pain of ischemic origin (Review).

8. These data suggested that hsa_circ_0004904 and hsa_circ_0001855 combined with PAPP-A might be promising biomarkers for the detection of Preeclampsia. Bioinformatics analysis predicted that hsa_circ_0004904 and hsa_circ_0001855 miRNA sponges directly target PAPP-A.

9. higher first trimester serum values seem to be associated with placenta accreta in women with placenta previa

10. Studied the role of pregnancy-associated plasma protein A (PAPP-A) in the outcome of ischemic cerebrovascular disease.

11. maternal serum levels associated with small for gestational age neonates, preterm birth, and pre-eclampsia

12. PAPP-A and ProMBP are associated with increased risk of death in heart failure patients.

13. low levels not associated with high serum estradiol at controlled ovarian stimulation

14. PAPP-A C/C genotypes were more frequent among mothers with gestational diabetes than in control.

15. Elevated PAPP-A compared to other risk factors was a stronger predictor for future CV events 2 years post ACS in patients with type 2 diabetes mellitus.

16. PAPP-A, like CCS and CIMT, is a parameter that can be used to detect subclinical atherosclerosis.

17. Results suggest that links between PAPP-A concentrations in early pregnancy and subsequent glucose concentrations and blood pressures may be mediated by changes in insulin sensitivity (and secretion).

18. Collectively, these results identify PAPP-A as a pregnancy-dependent oncogene while also showing that extended lactation is protective against PAPP-A-mediated carcinogenesis.

19. Lower PlGF and higher PAPP-A and free beta-hCG levels were found in the fetal circulation of near-term severe preeclamptic pregnancies

20. PAPP-A 1224 SNP has a significant effect on the level and activity of PAPP-A in human follicles, suggesting that the follicular fluid level of bioactive insulin-like growth factor depends on the genotype.

Cow (Bovine) Pregnancy-Associated Plasma Protein A, Pappalysin 1 (PAPPA) interaction partners

1. study determined IGFR1 and PAPP-A expression both in follicles at different stages of development and in ovarian cysts; data indicate that animals with cystic ovarian disease (COD) have an altered regulation of the IGF system in the ovary and thus allow postulating IGFR1 expression and PAPP-A secretion as a modulator of IGF1 in cattle with COD

2. in preovulatory follicles, PAPP-A is responsible for IGF-dependent IGFBP-2 degradation

3. concluded that changes in granulosa cell PAPP-A mRNA levels do not occur during final preovulatory follicular development in cattle